Literature DB >> 19515796

Iptakalim: a new or just another KCO?

Alexandre D T Costa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515796     DOI: 10.1093/cvr/cvp193

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  4 in total

1.  A new antihypertensive drug ameliorate insulin resistance.

Authors:  Yan-xia Liu
Journal:  Acta Pharmacol Sin       Date:  2012-04       Impact factor: 6.150

Review 2.  ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target.

Authors:  Peter T Nelson; Gregory A Jicha; Wang-Xia Wang; Eseosa Ighodaro; Sergey Artiushin; Colin G Nichols; David W Fardo
Journal:  Ageing Res Rev       Date:  2015-07-28       Impact factor: 10.895

3.  Iptakalim ameliorates hypoxia-impaired human endothelial colony-forming cells proliferation, migration, and angiogenesis via Akt/eNOS pathways.

Authors:  Mengyu He; Ting Cui; Qing Cai; Hong Wang; Hui Kong; Weiping Xie
Journal:  Pulm Circ       Date:  2019-10-18       Impact factor: 3.017

Review 4.  Neuroprotective role of ATP-sensitive potassium channels in cerebral ischemia.

Authors:  Hong-shuo Sun; Zhong-ping Feng
Journal:  Acta Pharmacol Sin       Date:  2012-11-05       Impact factor: 6.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.